{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:12:01Z","timestamp":1779210721847,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Recent revisions to acute leukemia classification systems increasingly emphasize genetic drivers of disease; however, critical immunophenotypic features remain essential for accurate diagnosis and risk assessment. CD56, an isoform of the neural cell adhesion molecule, is expressed on natural killer (NK) cells but is aberrantly present across multiple acute leukemias, where it may contribute to diagnostic complexity and adverse clinical outcomes. This review highlights the diagnostic and clinical significance of CD56 expression in acute leukemias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We review current classification frameworks and relevant literature to examine the role of CD56 immunophenotyping in the evaluation and clinical significance of acute leukemias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CD56 expression is observed in a heterogeneous group of acute leukemias, including subsets of acute myeloid leukemia (AML), NK lymphoblastic leukemia, acute undifferentiated leukemia, and blastic plasmacytoid dendritic cell neoplasm (BPDCN). In AML, CD56 expression has been associated with extramedullary disease, treatment resistance, and inferior survival in several studies, including high-risk subgroups such as AML with the RAM immunophenotype. In NK lymphoblastic leukemia and BPDCN, CD56 represents a key but nonspecific marker that must be interpreted in conjunction with additional lineage-associated antigens and molecular features to avoid diagnostic misclassification. Acute undifferentiated leukemia frequently demonstrates CD56 expression in the absence of definitive lineage markers, further emphasizing the need for integrated diagnostic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Acute leukemias with CD56 expression represent a diagnostically challenging and biologically diverse group of neoplasms. While CD56 lacks lineage specificity, its detection by flow cytometry provides valuable information for differential diagnosis, risk stratification, and, in some settings, minimal residual disease assessment. Accurate classification requires careful integration of immunophenotypic, morphologic, and genetic data. As therapeutic strategies become increasingly risk-adapted and targeted, precise recognition of CD56-positive blastoid neoplasms is essential to optimize patient management and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag021","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:32:23Z","timestamp":1771677143000},"source":"Crossref","is-referenced-by-count":0,"title":["Acute leukemias with expression of CD56"],"prefix":"10.1093","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-3653","authenticated-orcid":false,"given":"Alexa J","family":"Siddon","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]},{"name":"Department of Pathology, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Kahlow","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga K","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center , Dallas, TX,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2026051912533962900_aqag021-B1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00432-015-1977-3","article-title":"Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis","volume":"141","author":"Xu","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026051912533962900_aqag021-B2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2016.119","article-title":"A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"30","author":"Brodersen","year":"2016","journal-title":"Leukemia"},{"key":"2026051912533962900_aqag021-B3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2141.2011.08870.x","article-title":"Aberrant T-cell antigen expression in B lymphoblastic leukaemia","volume":"155","author":"Hussein","year":"2011","journal-title":"Br J Haematol"},{"key":"2026051912533962900_aqag021-B4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V84.1.244.244","article-title":"HLA-DR-, CD33+, CD56+, CD16- myeloid\/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3","volume":"84","author":"Scott","year":"1994","journal-title":"Blood"},{"key":"2026051912533962900_aqag021-B5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood.V90.6.2417","article-title":"CD7+ and CD56+ myeloid\/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity","volume":"90","author":"Suzuki","year":"1997","journal-title":"Blood"},{"key":"2026051912533962900_aqag021-B6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/cncr.21268","article-title":"Blastic natural killer cell lymphoma\/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement","volume":"104","author":"Suzuki","year":"2005","journal-title":"Cancer"},{"key":"2026051912533962900_aqag021-B7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1186\/s12885-022-10460-3","article-title":"Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia","volume":"22","author":"Liang","year":"2022","journal-title":"BMC Cancer"},{"key":"2026051912533962900_aqag021-B8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.leu.2402174","article-title":"CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis","volume":"15","author":"Raspadori","year":"2001","journal-title":"Leukemia"},{"key":"2026051912533962900_aqag021-B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.blre.2005.08.002","article-title":"The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?","volume":"20","author":"Mason","year":"2006","journal-title":"Blood Rev"},{"key":"2026051912533962900_aqag021-B10","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood.V90.4.1643","article-title":"Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8; 21)(q22; q22)","volume":"90","author":"Baer","year":"1997","journal-title":"Blood"},{"key":"2026051912533962900_aqag021-B11","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2010-04-277434","article-title":"Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens","volume":"117","author":"Montesinos","year":"2011","journal-title":"Blood"},{"key":"2026051912533962900_aqag021-B12","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-12-889725","article-title":"NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML","volume":"133","author":"Sasca","year":"2019","journal-title":"Blood"},{"key":"2026051912533962900_aqag021-B13","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1002\/jha2.1052","article-title":"Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: comparison with other CD56-positive acute leukemias","volume":"6","author":"Hamdan","year":"2025","journal-title":"EJHaem"},{"key":"2026051912533962900_aqag021-B14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.15725","article-title":"CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity","volume":"184","author":"Masetti","year":"2019","journal-title":"Br J Haematol"},{"key":"2026051912533962900_aqag021-B15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"key":"2026051912533962900_aqag021-B16","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3324\/haematol.2017.169029","article-title":"Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children\u2019s Oncology Group protocol AAML0531","volume":"102","author":"Voigt","year":"2017","journal-title":"Haematologica"},{"key":"2026051912533962900_aqag021-B17","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.136.12.4480","article-title":"The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes","volume":"136","author":"Lanier","year":"1986","journal-title":"J Immunol"},{"key":"2026051912533962900_aqag021-B18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12272-019-01143-y","article-title":"Natural killer cells as a promising therapeutic target for cancer immunotherapy","volume":"42","author":"Kim","year":"2019","journal-title":"Arch Pharm Res"},{"key":"2026051912533962900_aqag021-B19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/s41379-021-00739-4","article-title":"Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group","volume":"34","author":"Weinberg","year":"2021","journal-title":"Mod Pathol"},{"key":"2026051912533962900_aqag021-B20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2141.1990.tb07873.x","article-title":"Clinicopathological features of acute undifferentiated leukaemia with a stem cell phenotype","volume":"76","author":"Brito-Babapulle","year":"1990","journal-title":"Br J Haematol"},{"key":"2026051912533962900_aqag021-B21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0165-4608(96)00127-6","article-title":"Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine cases","volume":"92","author":"Cuneo","year":"1996","journal-title":"Cancer Genet Cytogenet"},{"key":"2026051912533962900_aqag021-B22","doi-asserted-by":"crossref","first-page":"106301","DOI":"10.1016\/j.leukres.2020.106301","article-title":"Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database","volume":"89","author":"Qasrawi","year":"2020","journal-title":"Leuk Res"},{"key":"2026051912533962900_aqag021-B23","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41379-019-0263-3","article-title":"Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group","volume":"32","author":"Weinberg","year":"2019","journal-title":"Mod Pathol"},{"key":"2026051912533962900_aqag021-B24","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1182\/blood-2023-188592","article-title":"The ELN 2022 risk stratification has no impact on the dismal prognosis of patients with acute undifferentiated leukemia","volume":"142","author":"Krayem","year":"2023","journal-title":"Blood"},{"key":"2026051912533962900_aqag021-B25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-019-0262-0","article-title":"Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"9","author":"Beird","year":"2019","journal-title":"Blood Cancer J"},{"key":"2026051912533962900_aqag021-B26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.hoc.2020.01.001","article-title":"Blastic plasmacytoid dendritic cell neoplasm: the dermatologist\u2019s perspective","volume":"34","author":"Hirner","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026051912533962900_aqag021-B27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Murthy","year":"2018","journal-title":"Leuk Res"},{"key":"2026051912533962900_aqag021-B28","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","article-title":"Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response","volume":"32","author":"Sakamoto","year":"2018","journal-title":"Leukemia"},{"key":"2026051912533962900_aqag021-B29","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Rev. 4th ed.","author":"Swerdlow","year":"2017"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag021\/68339793\/aqag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag021\/68339793\/aqag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:53:52Z","timestamp":1779209632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag021\/8687581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag021","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"aqag021"}}